Drugs / ABP 206
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06054555 | Nov 2023 → Jan 2028 expected | melanoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05907122 | Jul 2023 → Mar 2025 | melanoma | Amgen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP 206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05907122 ↗ |
| Route | Intravenous | “given intravenously” NCT05907122 ↗ |